MARKET

VIRX

VIRX

Viracta Therapeutics Inc
NASDAQ
0.4890
-0.0060
-1.21%
After Hours: 0.4700 -0.019 -3.89% 19:30 12/07 EST
OPEN
0.5000
PREV CLOSE
0.4950
HIGH
0.5123
LOW
0.4781
VOLUME
146.76K
TURNOVER
0
52 WEEK HIGH
2.470
52 WEEK LOW
0.4400
MARKET CAP
18.89M
P/E (TTM)
-0.3955
1D
5D
1M
3M
1Y
5Y
Viracta Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 3d ago
Weekly Report: what happened at VIRX last week (1127-1201)?
Weekly Report · 3d ago
Viracta Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 11/29 01:02
Weekly Report: what happened at VIRX last week (1120-1124)?
Weekly Report · 11/27 09:28
Weekly Report: what happened at VIRX last week (1113-1117)?
Weekly Report · 11/20 09:28
Viracta Therapeutics Inc: Current report
Press release · 11/18 01:11
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Viracta Therapeutics (VIRX) and Gossamer Bio (GOSS)
TipRanks · 11/14 08:30
Weekly Report: what happened at VIRX last week (1106-1110)?
Weekly Report · 11/13 09:26
More
About VIRX
Viracta Therapeutics, Inc. is a precision oncology company focused on the treatment and prevention of virus-associated cancers. Its lead product candidate is an all-oral combination therapy of its investigational drug, nanatinostat, and the antiviral agent valganciclovir (Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label phase II basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II trial for the treatment of EBV+recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its Vecabrutinib is a selective, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK). VRx-510 is its preclinical-stage PDK-1 inhibitor. It is also investigating in pre-clinical studies the use of its epigenetic drug candidate, nanatinostat.

Webull offers Viracta Therapeutics Inc stock information, including NASDAQ: VIRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIRX stock methods without spending real money on the virtual paper trading platform.